Notices. 30-Day Notice of Information Collection Under Review: Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local) Crime Laboratories

4,287 words·~19 min read·/register/2006/10/20/06-8828·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4410-11-M DEPARTMENT OF JUSTICE Drug Enforcement Administration [OMB Number 1117-0034] Agency Information Collection Activities: Proposed Collection; Comments Requested ACTION: 30-Day Notice of Information Collection Under Review: Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local) Crime Laboratories. The Department of Justice (DOJ), Drug Enforcement Administration

(DEA)has submitted the following information collection request to the Office of Management and Budget

(OMB)for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** Volume 71, Number 167, page 51214 on August 29, 2006, allowing for a 60-day comment period. The purpose of this notice is to allow for an additional 30 days for public comment until November 20, 2006. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to

(202)395-5806. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection

(1)*Type of Information Collection:* Extension of a currently approved collection.

(2)*Title of the Form/Collection:* Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local) Crime Laboratories.

(3)*Agency form number, if any, and the applicable component of the Department sponsoring the collection: Form number:* none. Office of Diversion Control, Drug Enforcement Administration, U.S. Department of Justice.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* State, Local or Tribal Government. *Other:* None. *Abstract:* Information is needed from state and local laboratories to provide DEA with additional analyzed drug information for the National Forensic Laboratory Information System.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* It is estimated that there are one hundred fifty

(150)total respondents for this information collection. One hundred twenty

(120)respond monthly at .16 hour (10 minutes) for each response and thirty

(30)respond quarterly at .16 hour (10 minutes) for each response, for a total number of 1560 respondents.

(6)*An estimate of the total public burden (in hours) associated with the collection:* It is estimated that there are 259 annual burden hours associated with this collection. FOR FURTHER INFORMATION CONTACT: Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: October 16, 2006. Lynn Bryant, Department Clearance Officer, U.S. Department of Justice. [FR Doc. E6-17554 Filed 10-19-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration [OMB Number 1117-0038] Agency Information Collection Activities: Proposed Collection; Comments Requested ACTION: 30-Day Notice of Information Collection Under Review: Reporting and Recordkeeping for Digital Certificates. The Department of Justice (DOJ), Drug Enforcement Administration

(DEA)has submitted the following information collection request to the Office of Management and Budget

(OMB)for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** Volume 71, Number 169, page 51856 on August 31, 2006, allowing for a 60-day comment period. The purpose of this notice is to allow for an additional 30 days for public comment until November 20, 2006. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to

(1)*Type of Information Collection:* Extension of a currently approved collection.

(2)*Title of the Form/Collection:* Reporting and recordkeeping for digital certificates.

(3)*Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* *Form Numbers:* *DEA Form 251:* CSOS DEA Registrant Certificate Application. *DEA Form 252:* CSOS Principal Coordinator/Alternate Coordinator Certificate Application. *DEA Form 253:* CSOS Power of Attorney Certificate Application. *DEA Form 254:* CSOS Certificate Application Registrant List Addendum. CSOS Certificate Revocation. *Component:* Office of Diversion Control, Drug Enforcement Administration, Department of Justice.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract:* *Primary:* Business or other for-profit. *Other:* Non-profit, State and local government. *Abstract:* Persons use these forms to apply for DEA-issued digital certificates to order Schedule I and II controlled substances. Certificates must be renewed upon renewal of the DEA registration to which the certificate is linked. Certificates may be revoked and/or replaced when information on which the certificate is based changes.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* DEA estimates that the rule will affect 98,000 registrants and 145,000 certificate holders. The average time for completing the application for a digital certificate to order controlled substances is estimated to be from 0.72 hours to 1.24 hours. Certificate renewal is estimated to take 0.083 hours.

(6)*An estimate of the total public burden (in hours) associated with the collection:* As registrants adopt the electronic ordering, the annual burden hours would average 41,860 hours a year. During this period, DEA assumes that 70 percent of the certificate holders will apply for certificates. *For Further Information Contact:* Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: October 16, 2006. Lynn Bryant, Department Clearance Officer, Department of Justice. [FR Doc. E6-17555 Filed 10-19-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration [OMB Number 1117-0033] Agency Information Collection Activities: Proposed Collection; Comments Requested ACTION: 30-Day Notice of Information Collection Under Review: Report of Mail Order Transaction. The Department of Justice (DOJ), Drug Enforcement Administration

(DEA)has submitted the following information collection request to the Office of Management and Budget

(OMB)for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** Volume 71, Number 162, page 48943 on August, 22, 2006, allowing for a 60 day comment period. The purpose of this notice is to allow for an additional 30 days for public comment until November 20, 2006. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to

(202)395-5806. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.* , permitting electronic submission of responses. Overview of This Information Collection

(1)*Type of Information Collection:* Extension of a currently approved collection.

(2)*Title of the Form/Collection:* Report of Mail Order Transactions.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* Business or other for-profit. *Other:* None. *Abstract:* The Comprehensive Methamphetamine Control Act of 1996 (Pub. L. 104-237)

(MCA)amended the Controlled Substances Act to require that each regulated person who engages in a transaction with a non-regulated person which involves ephedrine, pseudoephedrine, or phenylpropanolamine (including drug products containing these chemicals) and uses or attempts to use the Postal Service or any private or commercial carrier shall, on a monthly basis, submit a report of each such transaction conducted during the previous month to the Attorney General.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* There are twenty-four

(24)total respondents for this information collection. Fourteen

(14)responded on paper at 1 hour for each response and ten

(10)responded at 15 minutes per form, for an annual burden of 168 hours for paper forms and 30 hours for electronic forms.

(6)*An estimate of the total public burden (in hours) associated with the collection* : It is estimated that there are 198 annual burden hours associated with this collection. FOR FURTHER INFORMATION CONTACT: Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street NW., Washington, DC 20530. Dated: October 16, 2006. Lynn Bryant, Department Clearance Officer, Department of Justice. [FR Doc. E6-17556 Filed 10-19-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration [OMB Number 1117-0029] Agency Information Collection Activities: Proposed Collection; Comments Requested ACTION: 30-Day Notice of Information Collection Under Review: Annual Reporting Requirement for Manufacturers of Listed Chemicals. The Department of Justice (DOJ), Drug Enforcement Administration (DEA), has submitted the following information collection request to the Office of Management and Budget

(OMB)for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** Volume 71, Number 162, page 48943-49384 on August 22, 2006, allowing for a 60-day comment period. The purpose of this notice is to allow for an additional 30 days for public comment until November 20, 2006. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to

(1)*Type of Information Collection:* Extension of a currently approved collection.

(2)*Title of the Form/Collection:* Annual Reporting Requirement for Manufacturers of Listed Chemicals.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* Business or other for-profit. *Other:* None. *Abstract:* This information collection permits the Drug Enforcement Administration to monitor the volume and availability of domestically manufactured listed chemicals. These listed chemicals may be subject to diversion for the illicit production of controlled substances. This information collection is required by law.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* It is estimated that there are one hundred

(100)total respondents for this information collection. One hundred

(100)persons respond at 4 hours per response.

(6)*An estimate of the total public burden (in hours) associated with the collection:* It is estimated that there are 400 annual burden hours associated with this collection. FOR FURTHER INFORMATION CONTACT: Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: October 16, 2006. Lynn Bryant, Department Clearance Officer, U.S. Department of Justice. [FR Doc. E6-17557 Filed 10-19-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-274N] Solicitation of Information on the Use of Phenethylamine-Related Compounds AGENCY: Drug Enforcement Administration (DEA), Department of Justice. ACTION: Notice, solicitation of information. SUMMARY: The DEA is soliciting information on substances that are related in chemical structure to phenethylamine (see supplementary information). The Controlled Substances Act (CSA), Title 21 of the United States Code (U.S.C.) § 812(c) schedule I (Title 21 of the Code of Federal Regulations

(CFR)§ 1308.11(d)), lists certain phenethylamines as schedule I controlled substances. Some phenethylamines that are not controlled under the CSA produce central nervous system effects that are similar to phenethylamines that are controlled under the CSA. DEA is requesting information to help determine the impact on business if these substances were to be placed under control in the CSA. DATES: Written comments must be postmarked, and electronic comments must be sent, on or before December 19, 2006. ADDRESSES: To ensure proper handling of comments, please reference “Docket No. DEA-274N” on all written and electronic correspondence. Written comments being sent via regular mail should be sent to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL. Written comments sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, VA 22301. Comments may be directly sent to DEA electronically by sending an electronic message to *dea.diversion.policy@usdoj.gov.* DEA will accept attachments to electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept any file format other than those specifically listed here. FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief, Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537; Telephone:

(202)307-7183. SUPPLEMENTARY INFORMATION: Phenethylamine is a compound in which the chemical structure is a benzene ring substituted with a 2-aminoethyl chain. Although phenethylamine itself is not a controlled substance, its chemical structure constitutes the skeletal makeup of phenethylamines listed in schedule I of the CSA, which are classified as hallucinogenic substances. Phenethylamines are also found in schedule II and IV of the CSA. Phenethylamine is sometimes substituted on the benzene ring or the 2-aminoethyl chain or both with various substituents. Title 21 CFR 1308.11(d) lists specific substituted phenethylamines in schedule I. Also included in schedule I are the salts, isomers, and salts of isomers of the listed phenethylamines. The term isomer, as used in this section, means the optical, geometric, and positional isomers. Individuals have published detailed methods of synthesis for substituted phenethylamines and have reported pharmacological effects based on user experiences. Law enforcement personnel encounter such phenethylamines, but because they are substituted differently than those listed or described in the CSA, they are not subject to direct control in schedule I. However, some of these substances can be treated as schedule I controlled substance analogues if intended for human consumption (21 U.S.C. 802(32); 813). DEA is soliciting information on

(1)the commercial uses for phenethylamines,

(2)activities involving research and development,

(3)phenethylamines as intermediates or analytical standards,

(4)import and domestic sources for phenethylamines, and

(5)any planned or anticipated uses for phenethylamines. DEA invites interested persons to provide any information on the uses of phenethylamines in industry, academia, research and development, or other applications. Both quantitative and qualitative information are sought. Although information is requested for all phenethylamine substances regardless of substitutions, DEA is particularly interested in phenethylamines that meet one or more of the following conditions: any compound structurally derived from phenethylamine, or from any N-alkylphenethylamine, any alpha-alkylphenethylamine, or any N-alkyl-alpha-alkylphenethylamine, by substitution on the ring to any extent with alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio, alkylhalide, alkylene-dioxy, acyloxy, or halide substituents, whether or not further substituted on the ring by one or more other univalent substituents. DEA is especially interested in learning of the uses of the following phenethylamines: 1,4-Dimethoxynaphthyl-2-ethylamine 1,4-Dimethoxynaphthyl-2-isopropylamine 2-(2,5-Dimethoxy-4-methylphenyl)-cyclopropylamine 2,3,4,5-Tetramethoxyamphetamine 2,3,4-Trimethoxyamphetamine 2,3,4-Trimethoxyphenethylamine 2,3,5-Trimethoxyamphetamine 2,3,6-Trimethoxyamphetamine 2,3-Dimethoxy-4,5-methylenedioxyamphetamine 2,4,5-Triethoxyamphetamine 2,4,5-Trimethoxyamphetamine 2,4,5-Trimethoxyphenethylamine 2,4,6-Trimethoxyamphetamine 2,4-Diethoxy-5-methoxyamphetamine 2,4-Dimethoxy-5-ethoxyamphetamine 2,4-Dimethoxyamphetamine 2,5,beta-Trimethoxy-4-methylphenethylamine 2,5-Bismethylthio-4-methylamphetamine 2,5-Diethoxy-4-methoxyamphetamine 2,5-Dimethoxy-3,4-methylenedioxyamphetamine 2,5-Dimethoxy-4,N-dimethylamphetamine 2,5-Dimethoxy-4-ethoxyamphetamine 2,5-Dimethoxy-4-propoxyamphetamine 2,5-Dimethoxy-alpha-ethyl-4-methylphenethylamine 2,5-Dimethoxy-beta-hydroxy-4-methylphenethylamine 2,5-Dimethoxy-N,N-dimethyl-4-iodoamphetamine 2,5-Dimethoxy-N-hydroxy-4-(n)-propylthiophenethylamine 2,5-Dimethoxy-N-hydroxy-4-(sec)-butylthiophenethylamine 2,5-Dimethoxy-N-hydroxy-4-ethylthiophenethylamine 2,5-Dimethoxyphenethylamine 2,N-Dimethyl-4,5-methylenedioxyamphetamine 2-Bromo-4,5-methylenedioxyamphetamine 2-Ethoxy-4,5-dimethoxyamphetamine 2-Methoxy-3,4-methylenedioxyamphetamine 2-Methoxy-4,5-diethoxyamphetamine 2-Methoxy-4,5-methylenedioxyamphetamine 2-Methoxy-4-methyl-5-methylsulfinylamphetamine 2-Methoxy-4-methyl-5-methylthioamphetamine 2-Methylthio-3,4-dimethoxyphenethylamine 2-Methylthio-3,4-methylenedioxyamphetamine 2-Methylthio-4,5-dimethoxyamphetamine 3,4,5,beta-Tetramethoxyphenethylamine 3,4,5-Triethoxyphenethylamine 3,4,5-Trimethoxyphenethylamine 3,4-Diethoxy-5-methoxyphenethylamine 3,4-Diethoxy-5-methylthiophenethylamine 3,4-Dimethoxy-5-ethoxyphenethylamine 3,4-Dimethoxy-5-propoxyphenethylamine 3,4-Dimethoxyamphetamine 3,4-Dimethoxy-beta-hydroxyphenethylamine 3,4-Dimethoxyphenethylamine 3,4-Dimethyl-2,5-dimethoxyamphetamine 3,4-Dimethyl-2,5-dimethoxyphenethylamine 3,4-Ethylenedioxy-5-methoxyamphetamine 3,4-Methylenedioxyphenethylamine 3,4-Norbornyl-2,5-dimethoxyamphetamine 3,4-Norbornyl-2,5-dimethoxyphenethylamine 3,4-Tetramethylene-2,5-dimethoxyamphetamine 3,4-Tetramethylene-2,5-dimethoxyphenethylamine 3,4-Trimethylene-2,5-dimethoxyamphetamine 3,4-Trimethylene-2,5-dimethoxyphenethylamine 3,5-Diethoxy-4-ethylthiophenethylamine 3,5-Diethoxy-4-methoxyphenethylamine 3,5-Diethoxy-4-methylthiophenethylamine 3,5-Dimethoxy-4-ethylthiophenethylamine 3,5-Dimethoxy-4-isopropoxyphenethylamine 3,5-Dimethoxy-4-methallyloxyphenethylamine 3,5-Dimethoxy-4-phenethyloxyphenethylamine 3,5-Dimethoxy-4-propoxyphenethylamine 3-Ethoxy-4-ethylthio-5-methoxyphenethylamine 3-Ethoxy-4-methoxy-5-methylthiophenethylamine 3-Ethoxy-5-ethylthio-4-methoxyphenethylamine 3-Ethoxy-5-methoxy-4-methylthiophenethylamine 3-Methoxy-4,5-methylenedioxyphenethylamine 3-Methoxy-4-ethoxyphenethylamine 3-Methylthio-2,4-dimethoxyphenethylamine 3-Methylthio-4,5-dimethoxyphenethylamine 4-(2-Fluoroethyl)-2,5-dimethoxyamphetamine 4-(2-Fluoroethylthio)-2,5-dimethoxyphenethylamine 4-(2-Methoxyethylthio)-2,5-dimethoxyphenethylamine 4-(sec)-Butylthio-2,5-dimethoxyphenethylamine 4-(tert)-Butylthio-2,5-dimethoxyphenethylamine 4,5-Diethoxy-3-ethylthiophenethylamine 4,5-Dimethoxy-3-ethylthiophenethylamine 4,5-Thiomethyleneoxy-2-methoxyamphetamine 4-Allyloxy-3,5-dimethoxyphenethylamine 4-Amyl-2,5-dimethoxyamphetamine 4-Benzyloxy-3,5-dimethoxyamphetamine 4-Bromo-2,5,beta-trimethoxyphenethylamine 4-Bromo-2,5-dimethoxy-N-methylamphetamine 4-Bromo-3,5-dimethoxyamphetamine 4-Butoxy-3,5-dimethoxyphenethylamine 4-Butyl-2,5-dimethoxyamphetamine 4-Chloro-2,5-dimethoxyamphetamine 4-Chloro-2,5-dimethoxyphenethylamine 4-Cyclopropylmethoxy-3,5-dimethoxyphenethylamine 4-Cyclopropylmethylthio-2,5-dimethoxyphenethylamine 4-Cyclopropylthio-2,5-dimethoxyphenethylamine 4-Ethoxy-3,5-dimethoxyamphetamine 4-Ethoxy-3,5-dimethoxyphenethylamine 4-Ethoxy-3-ethylthio-5-methoxyphenethylamine 4-Ethoxy-5-methoxy-3-methylthiophenethylamine 4-Ethyl-2,5-dimethoxyphenethylamine 4-Ethyl-2-methoxy-5-methylthioamphetamine 4-Ethyl-5-methoxy-2-methylthioamphetamine 4-Ethylthio-2,5-dimethoxyamphetamine 4-Ethylthio-2,5-dimethoxyphenethylamine 4-Fluoro-2,5-dimethoxyphenethylamine 4-Iodo-2,5-dimethoxyamphetamine 4-Iodo-2,5-dimethoxyphenethylamine 4-Isopropoxy-2,5-dimethoxyphenethylamine 4-Isopropylthio-2,5-dimethoxyamphetamine 4-Isopropylthio-2,5-dimethoxyphenethylamine 4-Isopropylthio-2,6-dimethoxyphenethylamine 4-Methoxy-2,3-methylenedioxyamphetamine 4-Methyl-2,5-dimethoxyphenethylamine 4-Methyl-2,6-dimethoxyamphetamine 4-Methyl-3,5-Dimethoxyphenethylamine 4-Methylseleno-2,5-dimethoxyphenethylamine 4-Methylthio-2,3-dimethoxyphenethylamine 4-Methylthio-2,5-dimethoxyamphetamine 4-Methylthio-2,5-dimethoxyphenethylamine 4-Methylthio-3,5-dimethoxyphenethylamine 4-Nitro-2,5-dimethoxyamphetamine 4-Nitro-2,5-dimethoxyphenethylamine 4-Phenylthio-2,5-dimethoxyamphetamine 4-Propyl-2,5-dimethoxyamphetamine 4-Propyl-2,5-dimethoxyphenethylamine 4-Propylthio-2,5-dimethoxyamphetamine 4-Propylthio-3,5-dimethoxyphenethylamine 4-Propynyloxy-3,5-dimethoxyphenethylamine 4-Thiobutoxy-3,5-dimethoxyphenethylamine 4-Trideuteromethyl-3,5-dimethoxyphenethylamine 5-Bromo-2,4-dimethoxyamphetamine 5-Ethoxy-2-methoxy-4-methylamphetamine 5-Methoxy-4-methyl-2-methylthioamphetamine 5-Methylthio-2,4-dimethoxyamphetamine alpha,alpha,N-Trimethyl-3,4-methylenedioxyphenethylamine alpha,alpha-Dimethyl-3,4-methylenedioxyphenethylamine alpha-Ethyl-3,4,5-trimethoxyphenethylamine alpha-Ethyl-3,4-methylenedioxyphenethylamine Benzofuran-2,2-dimethyl-5-methoxy-6-(2-aminopropane) Benzofuran-2-methyl-5-methoxy-6-(2-aminopropane) beta,beta-Dideutero-3,4,5-trimethoxyphenethylamine beta-Methoxy-3,4-methylenedioxyphenethylamine N-(2-Hydroxyethyl)-3,4-methylenedioxyamphetamine N-(2-Methoxyethyl)-3,4-methylenedioxyamphetamine N,alpha-diethyl-3,4-methylenedioxyphenethylamine N,N-Dimethyl-3,4-methylenedioxyamphetamine N-Allyl-3,4-methylenedioxyamphetamine N-Benzyl-3,4-methylenedioxyamphetamine N-Butyl-3,4-methylenedioxyamphetamine N-Cyclopropylmethyl-3,4-methylenedioxyamphetamine N-Ethyl-alpha-propyl-3,4-methylenedioxyphenethylamine N-Hydroxy-N-methyl-3,4-methylenedioxyamphetamine N-Isopropyl-3,4-methylenedioxyamphetamine N-Methoxy-3,4-methylenedioxyamphetamine N-Methyl-2,5-dimethoxyamphetamine N-Methyl-2-methoxy-4,5-methylenedioxyamphetamine N-Methyl-3,4-ethylenedioxyamphetamine N-Methyl-4-methoxyamphetamine N-Methyl-alpha-ethyl-3,4-methylenedioxyphenethylamine N-Methyl-alpha-propyl-3,4-methylenedioxyphenethylamine N-Propargyl-3,4-methylenedioxyamphetamine N-Propyl-3,4-methylenedioxyamphetamine Such information may be submitted to the Drug Enforcement Administration using the information in the ADDRESSES section above. Such information is requested on or before December 19, 2006. Information designated as confidential or proprietary will be treated accordingly. Confidential business information is protected from disclosure under Exemption 4 of the Freedom of Information Act, 5 U.S.C. 552(b)(4)(FOIA) and the Department of Justice procedures set forth in 28 CFR 16.8. Dated: October 11, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control. [FR Doc. E6-17523 Filed 10-19-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Federal Bureau of Investigation [OMB Number 1110-0001] Agency Information Collection Activities: Proposed Collection, Comments Requested ACTION: 30-day Notice of Information Collection Under Review: Revision of a currently approved collection Return A—Monthly Return of Offenses Known to the Police; Supplement to Return A—Monthly Return of Offenses Known to the Police. The Department of Justice, Federal Bureau of Investigation, Criminal Justice Information Services Division has submitted the following information collection request to the Office of Management and Budget

(OMB)for review and clearance in accordance with established review procedures of the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register** on April 27, 2006, Volume 71, Number 81, Pages 24868-24869 allowing for a 60-day comment period. The purpose of this notice is to allow for an additional 30 days for public comment until November 20, 2006. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to Gregory E. Scarbro, Unit Chief, Federal Bureau of Investigation, Criminal Justice Information Services Division (CJIS), Module E-3, 1000 Custer Hollow Road, Clarksburg, West Virginia 26306; facsimile

(304)625-3566. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Comments should address one or more of the following four points:

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(4)Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques of other forms of information technology, e.g., permitting electronic submission of responses. Overview of this information collection:

(1)*Type of information collection:* Revision of a currently approved collection.

(2)*The title of the form/collection:* Return A—Monthly Return of Offenses Known to the Police and Supplement to Return A—Monthly Return of Offenses Known to the Police.

(3)*The agency form number, if any, and the applicable component of the department sponsoring the collection:* Forms 1-720, 1-720a, 1-720b, 1-720c, 1-720d, 1-720e, and 1-706; Criminal Justice Information Services Division, Federal Bureau of Investigation, Department of Justice.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* City, county, State, Federal and tribal law enforcement agencies. This collection is needed to collect information on Part I offense, rate, trend, and clearance data as well as stolen and recovered monetary values of stolen property throughout the United States. Data are tabulated and published in the semiannual and preliminary reports and the annual Crime in the United States.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* There are approximately 17,499 law enforcement agency respondents at 10 minutes for hard copy and 5 minutes for electronic submissions for the Return A and 11 minutes for hard copy and 5 minutes for electronic submissions for the Supplement to Return A.

(6)*An estimate of the total public burden (in hours) associated with this collection:* There are approximately 48,755 hours, annual burden, associated with this information collection. FOR FURTHER INFORMATION CONTACT: Ms. Lynn Bryant, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: October 16, 2006. Lynn Bryant, Department Clearance Officer, United States Department of Justice. [FR Doc. E6-17553 Filed 10-19-06; 8:45 am] BILLING CODE 4410-02-P FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION Sunshine Act Meeting October 13, 2006. Time and Date: 10 a.m., Thursday, October 26, 2006. Place: The Richard V. Backley Hearing Room, 9th Floor, 601 New Jersey Avenue, NW., Washington, DC. Status: Open. Matters to be Considered: The Commission will consider and act upon the following in open session: *Secretary of Labor* v. *Hanson Aggregates New York, Inc.,* Docket No. YORK 2005-22-M. (Issues include whether the Administrative Law Judge erred when he granted the Secretary of Labor's motion for summary decision and found that the operator violated the requirement of 30 CFR 56.14211(c) that a raised component of mobile equipment must be secured to prevent accidental lowering when persons working on or around the equipment are exposed to the hazard of accidental lowering of the component). Any person attending this meeting who requires special accessibility features and/or auxiliary aids, such s sign language interpreters, must inform the Commission in advance of those needs, subject to 29 CFR 2706.150(a)(3) and 2706.160(d). FOR FURTHER INFORMATION CONTACT: Jean Ellen,

(202)434-9950/(202) 708-9300 for TDD Relay/1-800-877-8339 for toll free. Jean H. Ellen, Chief Docket Clerk. [FR Doc. 06-8828 Filed 10-18-06; 12:02 pm]

Connectionstraces to 6

Traces to 6 documents

CFR

U.S. Code

2 references not yet in our index

5 CFR 1320.10
Pub. L. 104-237

Citation graph

cites case law

Notices

30-Day Notice of Information Collection Under Review: Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local) Crime Laboratories

Cite5 CFR 1320.10

Pub. L.Pub. L. 104-237

Cites 8Cited by 0 across 0 sources